Lion TCR, a Singapore-headquartered clinical-stage biotech company, saw its losses widen by 27% in 2023 from a year earlier as it continues to operate on zero revenues, regulatory filings showed.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
